Skip to main content
. 2021 Oct 30;22(21):11802. doi: 10.3390/ijms222111802

Figure 3.

Figure 3

Effects of oral administration ω-3 PUFA on brain damage in ischemia-reperfusion (IR) kidney. (A) Representative immunofluorescence stain of subgranular zone of the hippocampal DG of the brain section: Immunofluorescent staining was performed using Ki67 in the brain. High power field (HPF), original magnification, 200×. Scale bar = 50 μm. (B) Representative immunofluorescence stain of subgranular zone of the hippocampal DG of brain section: Immunofluorescent staining was performed by using NeuN in the brain. Original magnification, 400×. Scale bar = 200 μm. (C) Representative Western blot of brain lysis: The brain of ω-3 PUFA-treated uremic mice showed decreased Bax, cleaved caspase3 expression, and increased Bcl2 expression compared to the brain of uremic mice. Additionally, PARP (85 kDa) expression was also reduced in the brain of ω-3 PUFA-treated uremic mice compared to the brain of uremic mice. (D) Representative TUNEL stain of the subgranular zone of the hippocampal DG of the brain section. Original magnification, 200×. Scale bar = 50 μm. * p < 0.001 vs. wt, # p < 0.001 vs. IR. Bar represents mean ± S.D. (wt, wild-type sham; ω-3, ω-3 PUFA oral administration sham; IR, IR renal injury in wild-type mice; ω-3+IR, IR renal injury in ω-3 PUFA oral administration mice).